Exelixis (NASDAQ:EXEL) just hit a speed bump. Oppenheimer downgraded the stock from Outperform to Perform, dialing back its price target to $33. The reason? Fresh data from ASCO-GI failed to prove that its next-gen cancer drug, zanzalintinib, has a meaningful edge over its blockbuster cabozantinib. That's a red flag for investors banking on the company's pipeline to fuel future growth. But let's not get ahead of ourselvesExelixis still boasts a rock-solid balance sheet, a 96% gross margin, and a stock that's climbed 39% in 2024, outpacing the Nasdaq Biotechnology Index. With cabozantinib sales jumping 11% year-over-year and new label expansions on the horizon, there's plenty to keep bulls interested.
The big question: Can zanzalintinib deliver? Exelixis is going all in, running six pivotal trials across multiple cancers, with results expected in late 2025. Analysts see blockbuster potentialpossibly $5 billion in U.S. sales by 2033but recent setbacks, like the CONTACT-02 trial missing its survival target in metastatic prostate cancer, have some investors wary. Meanwhile, the company's patent fight over cabozantinib is heating up. A favorable court ruling in October could extend exclusivity to 2030, keeping generics at bay and securing a longer revenue runway. But if that ruling gets overturned? The clock on its flagship drug runs out a lot sooner, which would force Exelixis to scramble for new growth drivers.
Wall Street is split. JMP Securities is sticking with its $41 target, betting on long-term pipeline success, while Oppenheimer is playing it safe at $33. To boost investor confidence, Exelixis is rolling out a $500 million share buybackalways a bullish signal. The company is guiding for 2025 revenues between $1.95 billion and $2.05 billion, but whether that's enough to keep the rally going depends on two things: zanzalintinib proving itself in trials and cabozantinib holding onto its patent protection. Bottom line? The next 12 months are make-or-break for Exelixis.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.